George D. Demetri, M.D.


Dr. Demetri currently serves at the Quick Family Chair in Medical Oncology and Director of the Sarcoma Center at Dana-Farber Cancer Institute, as well as Professor of Medicine at Harvard Medical School and Co-Director of the Ludwig Center at Harvard. He has dedicated his career to translational and clinical research aimed at developing clinical therapeutics from scientific mechanisms to treat life-threatening cancers. He is a pioneer in the development of multiple targeted cancer therapies, and research from his collaborative efforts has resulted in FDA and worldwide regulatory approvals of several cancer therapies, including imatinib (Gleevec®), sunitinib (Sutent®), regorafenib (Stivarga®), pazopanib (Votrient®), trabectedin (Yondelis®), and tazemetostat (Tazverik®). Dr. Demetri received his undergraduate degree in Biochemistry from Harvard College and medical degree from Stanford University School of Medicine, after which he completed his internal medicine residency and chief residency at the University of Washington Hospitals in Seattle, and subsequently trained in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School. He is also Chair of the Science Policy and Government Affairs Committee of the American Association for Cancer Research.

Scroll to Top